Quality-of-life assessment in oncology - Achievements and challenges

Acta Oncologica

Volumn 41, Issue 3, 2002, Pages 229-237

  Sprangers, M A G ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

COST EFFECTIVENESS; GENETIC ENGINEERING; PATIENT TREATMENT; TUMORS;

PROXY RESPONDENTS;

ONCOLOGY;

CANCER MORTALITY; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DOCTOR PATIENT RELATION; EVALUATION; HUMAN; INFORMATION PROCESSING; ONCOLOGY; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

HEALTH STATUS; HUMANS; NEOPLASMS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0036332033     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860260088764     Document Type: Review

References (86)

1. Assessment of quality-of-life outcomes
2. The quality of life committee of the clinical trials group of the National Cancer Institute of Canada: Organization and functions
3. Quality of life and psychosocial oncology research in Europe: State of the art
4. American Cancer Society's second workshop on methodology in behavioral and psychosocial cancer research
5. Measuring quality of life today: Methodological aspects
6. Conceptual and methodological problems in research on the quality of life in clinical medicine
7. Measuring quality of life in clinical trials: A taxonomy and review
8. The sickness impact profile: Development and final revision of a health status measure
9. The Nottingham health profile: Subjective health status medical consultations
10. The MOS 36-item health survey (SF-36). Conceptual framework and item selection
11. EuroQol: A new facility for the measurement of health-related quality of life
12. Measuring psychological and physical distress in cancer patients: Structure and application of the Rotterdam Symptom Checklist
13. Measuring the quality of life of cancer patients: The Functional Living-Index-Cancer: Development and validation
14. Cancer Rehabilitation Evaluation System-Short Form (CARES-SF): A cancer specific rehabilitation and quality of life instrument
15. The Functional Assessment of Cancer Therapy Scale: Development and validation of the general measure
16. The EORTC QLQ-C30: A quality of life instrument for use in international clinical trials in oncology
17. Assessment of quality of life during chemotherapy
18. The multidimensional fatigue inventory (MFI) psychometric qualities of an instrument to assess fatigue
19. The hospital anxiety and depression scale
20. The importance of measuring quality of life in phase I/II trials of cancer therapy - The effects of antibody targeted therapy: Part 1
21. Do quality of life assessments make a difference in the evaluation of cancer treatments?
22. Quality of life evaluation in oncological clinical trials - The EORTC model
23. Measurement of health state utilities for economic appraisal
24. The Q-TwiST method
25. The importance of quality-of-life endpoints in clinical trials to the practicing oncologist
26. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points
27. Measuring health-related quality of life in clinical trials that evaluate the role of chemotherapy in cancer treatment
28. The long-term survivors
29. Neuropsychological late effects
30. Achievement of life goals by adult survivors of modern treatment for childhood cancer
31. Long term social adjustment after treatment for childhood cancer
32. Cancer in adolescents and young adults - Psychosocial aspects: Long-term survivors
33. Examining the psychological consequences of surviving childhood cancer: Systematic review as a research method in pediatric psychology
34. Prognostic value of quality of life scores during chemotherapy for advanced breast cancer
35. Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer
36. Quality of life scores predict outcome in metastatic but not early breast cancer
37. Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic melanoma
38. Quality of life assessment, an independent prognostic variable for survival in lung cancer
39. Quality of life in lung cancer surgical adjuvant trials
40. Prognostic factors for patients with inoperable non-small cell lung cancer, limited disease
41. Relation between tumor size, quality of life, and survival in patients with colorectal liver metastases
42. Quality of life scores: An independent prognostic variable in a general population of cancer patients receiving chemotherapy
43. Psychosocial correlates of survival in advanced malignant disease
44. Psychogenic factors in predicting survival of breast cancer patients
45. Psychosocial predictors of survival in metastatic melanoma
46. Is quality of life predictive of the survival of patients with advanced non-small cell lung carcinoma?
47. On the receiving end: III. Measurement of quality of life during cancer chemotherapy
48. How are you feeling? Who wants to know? Patients' and oncologists' preferences for discussing health-related quality-of-life issues
49. The use of quality of life data in clinical practice
50. Applications of health status assessment measures in clinical practice: Overview of the third conference on advances in health status assessment
51. The effectiveness of the use of patient-based measures of health in routine practice in improving the process and outcomes of patient care: A literature review
52. Provision of feedback on perceived health status to health care professionals. A systematic review of its impact
53. Impact of computerized quality of life screening on physician behaviour and patient satisfaction in lung cancer outpatients
54. The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease: A review
55. The use of proxy respondents in health studies of the aged
56. Assessing quality of life after stroke: The value and limitations of proxy ratings
57. Positive psychosocial adjustment in potential bone marrow transplant recipients: Cancer as a psychosocial transition
58. Life satisfaction and well-being measures in ventilator assisted individuals with traumatic tetraplegia
59. Anxiety and depression in breast cancer patients at low risk of recurrence compared with the general population - A valid comparison?
60. Methodological approaches for assessing response shift in longitudinal health-related quality-of-life research
61. Integrating response shift into health-related quality-of-life research: A theoretical model
62. Clinical understanding and clinical implications of response shift
63. Interferon toxicity worse in retrospect; impact on Q-TWiST?
64. Quality-of-life as subjective experience: Reframing of perception in patients with colon cancer undergoing radical resection with or without adjuvant chemotherapy
65. The challenge of response shift for quality-of-life based clinical oncology research
66. Measuring response shift using the Schedule for Evaluation of Individual Quality of Life
67. Personal goals and response shifts: Understanding the impact of illness and events on the quality of life of people living with AIDS
68. Associations between health status and utilities: Indirect evidence for response shift
69. Internal invalidity in pretest - Posttest self-report evaluations and a reevaluation of retrospective pretests
70. Response shift in quality of life measurement in early-stage breast cancer patients undergoing radiotherapy
71. Response shift in prostate cancer patients: An evaluation of suppressor and buffer models
72. Revealing response shift in longitudinal research on fatigue: The use of the then-test approach
73. How response shift may affect the measurement of change in fatigue
74. Interpretation of quality of life changes
75. Measurement of health status: Ascertaining the minimal clinically important difference
76. Determining a minimal important change in a disease-specific quality of life questionnaire
77. Interpreting the significance of changes in health-related quality-of-life scores
78. Methodological problems in the retrospective computation of responsiveness to change: The lesson of Cronbach
79. Relation of distribution- and anchor-based approaches in interpretation of changes in health related quality of life
80. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States
81. Assessing quality of life in clinical research: From where have we come and where are we going?
82. Ethnicity and cancer outcomes: Behavioral and psychosocial considerations